The tumorigenic function of LINC00858 in cancer - 09/10/21
pages | 6 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Long non-coding RNA (lncRNA) plays an important regulatory role in the occurrence and development of human cancer. LINC00858 is a newly discovered lncRNA with a length of 2685 nucleotides. Existing studies have shown that LINC00858 has abnormally high expression levels in malignant tumors such as colorectal cancer, gastric cancer, hepatocellular carcinoma, lung cancer, non-small cell lung cancer, ovarian cancer, osteosarcoma, retinoblastoma, Wilms tumor, bladder cancer, and cervical cancer. By regulating a variety of microRNAs, LINC00858 can affect tumor cell proliferation, invasion, metastasis, and apoptosis. Related research also found that LINC00858 is related to nuclear transcription factor/protein kinase and gene methylation. The aberrant expression of LINC00858 is related to the prognosis and clinicopathological characteristics of a variety of tumors. Overexpressed LINC00858 is closely related to the clinical stage, lymph node metastasis, and distant metastasis of cancer, including colorectal cancer, gastric cancer, non-small cell lung cancer, ovarian cancer, and Wilms tumor. Also, it is summarized that LINC00858 can regulate MAPK and TGF-β signaling pathways. This review shows that LINC00858 as an important oncogene can promote tumorigenesis and cancer development.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | LINC00858 is an oncogene that affects tumor cell proliferation, invasion, metastasis, and apoptosis through sponging miRNAs. |
• | LINC00858 participates in the MAPK signaling pathway and TGF-β signaling pathway. |
• | The expression level of LINC00858 is closely related to the prognosis and clinicopathological characteristics of cancer patients. |
Keywords : LINC00858, Cancer, CeRNA, MAPK, TGF-β
Plan
Vol 143
Article 112235- novembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?